Focus : Which are the antibodies to watch in 2013?

The start of the New Year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies  (mAbs) in active Phase 2/3 or Phase 3 clinical studies.  the entire clinical pipeline currently includes ~350 mAbs, but most of these are in early development. As of the beginning of 2013, our “Antibodies to watch” list includes 28 single mAbs and one mAb mixture that are undergoing evaluation in Phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, Alzheimer disease and infectious disease. in alphabetical order, the  28 mabs are alirocumab, AMG 145, elotuzumab, epratuzumab, farletuzumab, gantenerumab, gevokizumab, inotuzumab, ozogamicin, itolizumab, ixekizumab, lebrikizumab, mepolizumab, naptumomab estafenatox, necitumumab, nivolumab,  obinutuzumab, ocrelizumab, onartuzumab, racotumomab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sirukumab, solanezumab, tabalumab, and vedolizumab. the mixture of actoxumab and bezlotoxumab is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.

INN or code name	Molecular type	Target(s)	Current phase	Phase 2/3 or 3 indications
Naptumomab estafenatox (ABR-217620)	Murine Fab immunotoxin	Trophoblast glycoprotein, also known as TPBG or 5T4	Phase 2/3	Renal cell carcinoma
Ramucirumab	Human IgG1	VEGFr2	Phase 3	Gastric; liver, breast, colorectal, NSCL cancers
Farletuzumab	Humanized IgG1	Folate receptor α	Phase 3	Ovarian cancer
Obinutuzumab	Humanized IgG1	CD20	Phase 3	diffuse large B cell lymphoma, CLL, NHL
Elotuzumab	Humanized IgG1	CD2	Phase 3	Multiple myeloma
Inotuzumab ozogamicin	Humanized IgG4	AdC CD22	Phase 3	ALL; NHL
Necitumumab	Human igG1	EGFr	Phase 3	NSCL cancer
Onartuzumab	Humanized IgG1 Fab-Fc	cMet	Phase 3	NSCL cancer; gastric cancer
Racotumomab	Murine	GM3	Phase 3	NSCL cancer

Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of cancer indications. Table compiled from information available as of November 15, 2012. ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; NHL, nonHodgkin lymphoma; VEGFr2, vascular endothelial growth factor receptor 2, NSCL, non-small-cell lung.

Source: Which are the antibodies to watch in 2013? Janice M. Reichert. mAbs 5:1, 1–4; January/February 2013

Free paper available at:

http://www.landesbioscience.com/journals/mabs/2012MABS0502.pdf